Abstract
Efficacy and Safety of ES-481, a Novel TARP Inhibitor, in Drug-resistant Epilepsy: A Double-blind Randomized Placebo Controlled Phase IIa Trial (S19.003)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have